By Chris Kohler
Mesoblast has extended its loss in fiscal 2014 but sees continued progress in clinical products in the year ahead and will continue to focus on strategic partnerships.
Alan has been a trusted source of investment advice to Australians for many years, and in 2005 he founded Eureka Report - Australia’s #1 online investment report.
In the 12 months to June 30, the biotechnology company recorded a net loss of $80. 9 million, a 31. 3 per cent fall from the $60. 1m loss posted a year ago.
The company said the extended loss is due to increased investment in clinical development, commercial manufacturing and investment in employees.
Read more here: Business Spectator